Simple blood test could offer hope to patients with treatment-resistant lupus
It is hoped the test, which looks for certain biomarkers in the blood, could help these patients get access to a combination therapy on the health service in the future.
Previous studies have shown patients with treatment-resistant lupus who are positive for the biomarker are 17 times more likely to respond to the drugs, which are available on the NHS but not currently used together.
As part of a £1.7 million trial – known as Stratify Lupus – experts will test the blood of people with lupus that has not responded to conventional therapies such as steroids or immune suppressants.
If they are shown to have the biomarker, researchers will give them either the combination therapy or placebo.
Michael Ehrenstein, consultant rheumatologist at University College London Hospitals and professor of experimental rheumatology at University College London (UCL), is leading the research.
He said: 'If the results are positive then we would apply to allow patients who are positive for the biomarker to receive the combination therapy on the NHS.
'Targeting the patients most likely to benefit from this treatment should make it deliverable on the NHS and improve patient access and outcomes.'
The study will begin in spring 2026 at 16 hospitals across the UK and is expected to finish in 2029.
Lupus is a chronic autoimmune condition where the body's immune system mistakenly attacks healthy tissues and organs.
Prof Ehrenstein's previous research found a combination of the drugs rituximab and belimumab was able to bring lupus under control, and significantly reduce severe flare-ups in some, but not all, patients.
Both drugs are treatment options for lupus patients, but are not used in combination.
They are targeted therapies known as monoclonal antibodies.
These are lab-produced identical copies of a single type of antibody, which are the proteins produced by the immune system to attack the likes of bacteria and viruses.
Prof Ehrenstein's team identified a biomarker in the blood of about half of lupus patients who were resistant to conventional treatment.
Known as IgA2 anti-dsDNA, those with the biomarker were 17 times more likely to respond to a combination of rituximab and belimumab compared to rituximab alone.
It is estimated that up to 69,000 people in the UK have lupus, which mostly affects women and those of African, Caribbean and Asian descent.
It can range from mild to severe, with symptoms including joint pain, skin problems, fatigue and inflammation of major organs.
People often take drugs for life, ranging from steroid tablets and injections, or other immunosuppressant or biological medicines.
Prof Ehrenstein added: 'To have a positive result in a personalised medicine trial for lupus would be globally significant, not only for the biomarker and treatment combination, but also the success of this targeted approach.
'Everyone talks about personalised medicine, but so far this goal has not been achieved in inflammatory/autoimmune rheumatic diseases.
'Stratify Lupus will be the first biomarker enrichment trial for lupus, which is a real coup for UK research.'
The study is being funded by the charity Versus Arthritis and the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC).
Professor Lucy Donaldson, director of research at Versus Arthritis, said: 'This major trial holds real promise of a better future for those living with lupus, which particularly affects underserved people.
'Too few advances have been made in tackling the devastating disease which mainly affects women, in particular women of African and Caribbean heritage, in the prime of their lives.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
33 minutes ago
- Powys County Times
NHS waiting list for planned treatment falls to lowest level in two years
The NHS waiting list for planned hospital treatment has fallen to its lowest level for two years, figures show. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. These are the lowest figures since March 2023 for treatments and April 2023 for patients. The news comes after Chancellor Rachel Reeves gave the NHS a cash injection worth an extra £29 billion per year. Health and Social Care Secretary Wes Streeting said: 'We are putting the NHS on the road to recovery after years of soaring waiting times, by providing record investment and fundamental NHS reform. 'Thanks to our interventions and the hard work of NHS staff, the overall waiting list has now fallen in April for the first time in 17 years – dropping by almost a quarter of a million since we took office. 'This is just the start. We've delivered millions of extra appointments since July, we are pushing on with our mission to get the NHS working for patients once again as we deliver our Plan for Change.' Within the new NHS figures, the number of longer waits has grown. Some 1,361 patients in England had been waiting more than 18 months to start routine treatment at the end of April, up from 1,164 in March. There were 9,258 patients who had been waiting more than 65 weeks to start treatment, up from 7,381 the previous month. Overall, 190,068 people in England had been waiting more than 52 weeks to start routine hospital treatment, up from 180,242 at the end of March. The figure had previously fallen for 10 months in a row. NHS England said that, overall, the average time patients had been waiting for planned treatment fell to the lowest level since July 2022 – 13.3 weeks – despite services facing greater demand. Meghana Pandit, NHS England's co-national medical director, said NHS staff were working to 'turn the tide for patients waiting for care'. She said while huge pressure on services remains, 'we are starting to see a real difference across our services – this is just the start of the work we're doing to reform care and deliver improvements for patient'. The data also showed fewer people are getting a diagnosis of cancer or having it ruled out within four weeks. A total of 76.7% of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in April, down from 78.9% in March and 80.2% in February. The Government and NHS England had set a target of March 2026 for this figure to reach 80%. The proportion of patients who had waited no longer than 62 days in April from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 69.9%, down from 71.4% in March. GPs in England made 264,880 urgent cancer referrals in April, down from 272,165 in March but up year-on-year from 260,516 in April 2024. Rory Deighton, acute director at the NHS Confederation, said: 'This new data shows that the hard work of NHS leaders and their teams is paying off, with waiting lists falling to their lowest level in two years and A&E performance increasing despite incredibly high demand. 'But our members know there is still a long way to go to further drive down waiting lists and hit the 18-week target.' He said the money pledged by the Chancellor was welcome 'but there are fears that this uplift will not be enough to achieve all the Government's manifesto pledges, including hitting the stretching 92% elective waiting time target by March 2029. 'Many of our members have warned they will not hit the interim target, with only one in two confident they will achieve the 65% elective care interim target by March 2026. 'The solution lies in the radical redesign of pathways, in particular outpatient services, which many of our members are already working towards. 'We look forward to working with them to spread best practice across the country.'
Western Telegraph
an hour ago
- Western Telegraph
Council tax bills set to rise at fastest rate for two decades, economist warns
Paul Johnson said that local government in England did 'perhaps a little bit better than it might have expected' out of the Chancellor's statement on Wednesday, but the 'sting in the tail' is the assumption that 'council tax bills will rise by 5% a year' as part of the funding. The core spending power of councils is set to increase by 2.6% a year from next year, and 'if English councils do choose 5% increases – and most almost certainly will – council tax bills look set to rise at their fastest rate over any parliament since 2001-05', Mr Johnson said on Thursday. On Wednesday, Ms Reeves said that ministers will not be 'going above' the 5% annual increases in council tax. (PA Graphics) She told ITV: 'The previous government increased council tax by 5% a year, and we have stuck to that. We won't be going above that. 'That is the council tax policy that we inherited from the previous government, and that we will be continuing.' The biggest winner from Wednesday's statement was the NHS, which will see its budget rise by £29 billion per year in real terms. Ruth Curtice, the chief executive of the Resolution Foundation, has said that Britain is turning into a 'National Health State'. Overnight, the think tank said Ms Reeves' announcements had followed a recent trend that saw increases for the NHS come at the expense of other public services. Ms Curtice said: 'Health accounted for 90% of the extra public service spending, continuing a trend that is seeing the British state morph into a National Health State, with half of public service spending set to be on health by the end of the decade.' Defence was another of Wednesday's winners, Ms Curtice said, receiving a significant increase in capital spending while other departments saw an overall £3.6 billion real-terms cut in investment. The Institute for Fiscal Studies (IFS) made similar arguments about 'substantial' investment in the NHS and defence coming at the expense of other departments, although Mr Johnson warned on Wednesday the money may not be enough. In his snap reaction to the review, Mr Johnson said: 'Aiming to get back to meeting the NHS 18-week target for hospital waiting times within this Parliament is enormously ambitious – an NHS funding settlement below the long-run average might not measure up. 'And on defence, it's entirely possible that an increase in the Nato spending target will mean that maintaining defence spending at 2.6% of GDP no longer cuts the mustard.' Ms Curtice added that low and middle-income families had also done well out of the spending review 'after two rounds of painful tax rises and welfare cuts', with the poorest fifth of families benefiting from an average of £1,700 in extra spending on schools, hospitals and the police. She warned that, without economic growth, another round of tax rises was likely to come in the autumn as the Chancellor seeks to balance the books. She said: 'The extra money in this spending review has already been accounted for in the last forecast. 'But a weaker economic outlook and the unfunded changes to winter fuel payments mean the Chancellor will likely need to look again at tax rises in the autumn.' Speaking after delivering her spending review, Ms Reeves insisted she would not have to raise taxes to cover her spending review. She told GB News: 'Every penny of this is funded through the tax increases and the changes to the fiscal rules that we set out last autumn.'
The Independent
an hour ago
- The Independent
NHS waiting list for planned treatment falls to lowest level in two years
The NHS waiting list for planned hospital treatment has fallen to its lowest level for two years, figures show. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. These are the lowest figures since March 2023 for treatments and April 2023 for patients. The news comes after Chancellor Rachel Reeves gave the NHS a cash injection worth an extra £29 billion per year. Health and Social Care Secretary Wes Streeting said: 'We are putting the NHS on the road to recovery after years of soaring waiting times, by providing record investment and fundamental NHS reform. 'Thanks to our interventions and the hard work of NHS staff, the overall waiting list has now fallen in April for the first time in 17 years – dropping by almost a quarter of a million since we took office. 'This is just the start. We've delivered millions of extra appointments since July, we are pushing on with our mission to get the NHS working for patients once again as we deliver our Plan for Change.' Within the new NHS figures, the number of longer waits has grown. Some 1,361 patients in England had been waiting more than 18 months to start routine treatment at the end of April, up from 1,164 in March. There were 9,258 patients who had been waiting more than 65 weeks to start treatment, up from 7,381 the previous month. Overall, 190,068 people in England had been waiting more than 52 weeks to start routine hospital treatment, up from 180,242 at the end of March. The figure had previously fallen for 10 months in a row. NHS England said that, overall, the average time patients had been waiting for planned treatment fell to the lowest level since July 2022 – 13.3 weeks – despite services facing greater demand. Meghana Pandit, NHS England's co-national medical director, said NHS staff were working to 'turn the tide for patients waiting for care'. She said while huge pressure on services remains, 'we are starting to see a real difference across our services – this is just the start of the work we're doing to reform care and deliver improvements for patient'. The data also showed fewer people are getting a diagnosis of cancer or having it ruled out within four weeks. A total of 76.7% of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in April, down from 78.9% in March and 80.2% in February. The Government and NHS England had set a target of March 2026 for this figure to reach 80%. The proportion of patients who had waited no longer than 62 days in April from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 69.9%, down from 71.4% in March. GPs in England made 264,880 urgent cancer referrals in April, down from 272,165 in March but up year-on-year from 260,516 in April 2024. Rory Deighton, acute director at the NHS Confederation, said: 'This new data shows that the hard work of NHS leaders and their teams is paying off, with waiting lists falling to their lowest level in two years and A&E performance increasing despite incredibly high demand. 'But our members know there is still a long way to go to further drive down waiting lists and hit the 18-week target.' He said the money pledged by the Chancellor was welcome 'but there are fears that this uplift will not be enough to achieve all the Government's manifesto pledges, including hitting the stretching 92% elective waiting time target by March 2029. 'Many of our members have warned they will not hit the interim target, with only one in two confident they will achieve the 65% elective care interim target by March 2026. 'The solution lies in the radical redesign of pathways, in particular outpatient services, which many of our members are already working towards. 'We look forward to working with them to spread best practice across the country.'
